Working draft — Scientific review: pending | Regulatory review: pending | Not for external clinical or promotional use without independent verification
Specialist Prescriber Education

Prescriber Education Hub

A structured education programme for specialist prescribers of cannabinoid medicines. 13 modules covering source governance, pharmacology, evidence assessment, patient selection, dosing, safety, clinical pathways, consent, and clinic governance.

13
Education Modules
39
Downloadable Tools
17+
Quiz Questions
80%
Pass Mark

Evidence-Status Badges Used Throughout

Regulatory approvedPublished RCTPublished pilotObservational / case seriesActive trialPreclinical / mechanisticMixed / negativeCSR pendingLegal confirmation requiredPrescriber-onlyTopical onlyLocal formulation only

Education System Architecture

Layer A

Public Educational Portal

Evidence matrix, patient education, interaction guide, clinic redirect. Product-agnostic and non-promotional.

Layer B

Prescriber Education Hub

Education modules, checklists, monitoring tools, consent templates. Can reference NWPT-SM32300 in prescriber-only modules.

Layer C

NWPT-SM32300 Scientific Module

Prescriber-only, source-controlled, non-promotional. IB-aligned scientific information with CSR validation requirements.

Module Library

Complete all modules and achieve 80% on the final assessment to receive certification.

Clinical Tools and Templates

Each module includes downloadable tools for clinical practice. Access them within individual module pages.

Prescriber checklist
Patient suitability form
Baseline assessment form
Medication review form
Interaction checklist
LFT monitoring template
Adverse-event form
Informed consent template
Follow-up template
Stopping criteria template
Clinic audit dashboard

This material is educational and non-promotional. It does not constitute medical advice, prescribing advice, or a recommendation to use any medicine. Any use of an unlicensed medicine requires patient-specific clinical justification, informed consent, monitoring, pharmacovigilance and compliance with applicable regulatory requirements.